Blog
Cancer evolution converging on common resistance mechanisms to PARP inhibition: A Molecular Tumor Board discussion.
Precision oncology is revolutionizing the way we treat cancer by tailoring therapies to the genetic makeup of individual tumors. As our understanding of cancer's molecular biology continues to expand, therapies are becoming more targeted, effective, and...
Bridging liquid biopsy discoveries with clinical cancer: Harnessing ctDNA Molecular Response to Predict Clinical Outcomes and Guide Therapeutic Decision Making for Individuals with Lung Cancer.
Posing hypothesis-driven and clinically relevant questions represents one of the pillars of scientific discovery that can be translated in interventions that may improve patient outcomes. And that’s exactly what our research team was able to do with BR.36; a...
Dual Insights in a Blood Draw: Cancer and Immune Cell Footprints in Blood Tests Capture Immunotherapy Outcomes and Toxicity for Patients with Lung Cancer.
Dual Insights in a Blood Draw: Cancer and Immune Cell Footprints in Blood Tests Capture Immunotherapy Outcomes and Toxicity for Patients with Lung Cancer.